BioNJ Elects New Officers; Adds Five New Members to Board of Trustees

TRENTON (January 23, 2009) — BioNJ, New Jersey’s trade association for bioscience companies, announced today that at its January 22, 2009 Annual Meeting, Dinner and Awards Program the Board of Trustees named new officers and elected five new members. The mission of the Board is to help foster a positive culture for biotechnology companies to prosper in New Jersey.

Geert Cauwenbergh, Ph.D., Chairman and Chief Executive Officer (CEO) of RHEI Pharmaceuticals and Managing Director of Phases 123 LLC, was named Chairman; Lisa N. Drakeman, Ph.D., CEO of Genmab, was named Vice Chairman; Anthony Marucci, President and CEO of Celldex Therapeutics was elected Treasurer; and Sol J. Barer, Ph.D., Chairman and CEO of Celgene Corporation was elected Secretary.

Elected to their first terms as members-at-large were: Laurie Smaldone Alsup, M.D., CEO of Phytomedics, Inc.; Roger Berlin, M.D., FACP, FACG, CEO of Arno Therapeutics, Inc.; John Johnson, CEO of ImClone Systems, Inc.; Mr. Marucci; and Christopher J. Schaber, Ph.D., President and CEO of DOR BioPharma, Inc..

The new board members join returning board members: John Crowley, President and CEO of Amicus Therapeutics; Michael DuBois, Senior Vice President, Global Licensing and Strategic Alliances at Schering-Plough Corporation; Ulrich Grau, Ph.D., Founder, President and CEO of Lux Biosciences; and Tamar Howson of JSB Partners, Corporate and Business Development.

Also returning are: Richard Kender, Senior Vice President, Business Development and Corporate Licensing at Merck and Company, Inc.; Christian Kopfli, Esq., CEO of Chromocell; Frank LaSaracina, Principal of SouthPoint Associates LLC; John Maki, President and CEO of Vicus Therapeutics; Marvin L. Miller, Director at Unigene Laboratories; Stuart W. Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc.; Elizabeth G. Posillico, Ph.D., President and CEO of Elusys Therapeutics, Inc.; and Gary Reedy, Worldwide Vice President, Biopharmaceutical Public Policy and Services at Johnson and Johnson.

The Board yesterday also presented Michael D. Becker with the Chairmans Award. Mr. Becker, who is President and CEO of MD Becker Partners, LLC, served as BioNJ Chairman in 2007 and 2008. BioNJ also recognized it former Treasurer, Mr. LaSaracina, and former Board Members, Elizabeth Tallett, Principal of Hunter Partners, LLC, and Paul G. Thomas, former President, CEO and Chairman of LifeCell Corporation.


BioNJ Chairman
Geert Cauwenbergh, Ph.D.
Chairman and CEO, RHEI Pharmaceuticals

Prior to joining RHEI Pharmaceuticals of Plainsboro, NJ, in February 2008 as Chairman and CEO, Dr. Cauwenbergh founded Phases 123 LLC, a company focused on identifying high potential health care technology platforms and emerging health care companies. In 2001, Dr. Cauwenbergh founded Barrier Therapeutics, Inc., a company developing novel patented therapeutic agents for treatment of skin diseases. Under his leadership, Barrier Therapeutics went public and raised a total of $250 million in capital, evolving from an R&D organization into a commercial company with expected revenues of $45 million in 2008, prior to its recent acquisition by Stiefel Laboratories.

RHEI Pharmaceuticals (RHEI) of Plainsboro, NJ, is a specialty pharmaceutical company focused on bringing core medicines from the U.S., Europe and Japan, into the fast-growing marketplace in China.

BioNJ Vice-Chair
Lisa N. Drakeman, Ph.D.
CEO, Genmab

Dr. Drakeman has served as Genmab’s President and CEO since the company’s inception in 1999. Dr. Drakeman has over 18 years of experience working in the biotechnology industry, including establishing corporate partnerships with major pharmaceutical companies, managing clinical trials of monoclonal antibody-based products and developing government programs for financing biotechnology research.

At Genmab, she has set a number of financing records, including the largest private investment ever for a biotech company, the largest IPO ever by a European biotech company and the largest biotech licensing transaction worldwide with GlaxoSmithKline for ofatumumab, a fully human, high-affinity antibody that is being developed under a worldwide co-development and commercialization agreement with GlaxoSmithKline (GSK) for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, diffuse large B-cell lymphoma and remitting relapsing multiple sclerosis.

Genmab of Princeton, NJ is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.

BioNJ Treasurer
Anthony Marucci
President and CEO, Celldex Therapeutics

Anthony Marucci was a founder of Celldex and served as Vice President, Chief Financial Officer, Treasurer and Secretary from May 2003 until his appointments as Executive Vice President in March 2008, President and Chief Executive Officer in October 2008 and to the Board of Directors in December 2008.

He was responsible for the asset acquisition of CDX-110, an investigational immunotherapy being studied in cancer therapy, from Alteris Therapeutics, Inc. and the acquisition of Lorantis Limited (Cambridge, UK), as well as the AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. merger completed during the first quarter of 2008.

Celldex Therapeutics of Phillipsburg, NJ is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases.

BioNJ Secretary
Sol J. Barer, Ph.D
Chairman and CEO, Celgene Corporation

Sol J. Barer, Ph.D., has been CEO of Celgene Corporation, a multinational biopharmaceutical company located in Summit, NJ, since May 1, 2006, and Chairman since January 1, 2007. He was appointed President in 1993, Chief Operating Officer and Director in 1994 and is a member of the Executive Committee of the Board of Directors.

He founded the biotechnology group at Celanese that was subsequently spun out to form Celgene. Celgene is currently one of the worlds largest biotechnology companies with a market capitalization of over $20 billion.

Dr. Barer is also on the Board of Trustees of Rutgers University, Board of Directors of PhRMA, serves on the Board of Directors of Amicus Therapeutics and is on the Board of the Brooklyn College Foundation. He has previously served as a Commissioner of the New Jersey Commission on Science and Technology.


Laurie Smaldone Alsup, M.D.
President and CEO, Phytomedics, Inc.

Dr. Laurie Smaldone Alsup joined Phytomedics, Inc. as President and CEO in 2008. Phytomedics of Jamesburg, NJ is focused on the discovery, development, manufacture, and commercialization of novel, multi-component and multi-functional drugs from natural sources.

Prior to Phytomedics, Dr. Alsup served in numerous capacities at Bristol-Myers Squibb between 1985 and 2007 including, Vice President of Corporate Strategy and Issues Management; Sr. Vice President Global Regulatory Science; Vice President Worldwide Medical Services and Labeling; Vice President Infectious Diseases Clinical Research; Executive Director, HIV/Antiviral Clinical Research; Executive Director, Clinical Cancer Research; and Director, Clinical Cancer Research.

Dr. Alsup served as Assistant Clinical Professor of Medicine, Yale School of Medicine from 1985 to 1992 and as Instructor in Medicine, Attending for General Medicine and Oncology at Yale from 1984 to1985.

Roger Berlin, M.D., FACP, FACG
CEO, Arno Therapeutics, Inc.

Dr. Roger Berlin has over 20 years of drug development experience in multiple therapeutic categories, which have led to numerous NDA, sNDA and MRP approvals. Prior to joining Arno Therapeutics, Dr. Berlin was President, Global R&D at Wyeth Consumer Healthcare, the $2.7 billion non-prescription division of Wyeth, from 1998 to 2008, previously serving in various positions of increasing responsibility since 1994.

Before joining Wyeth, Dr. Berlin served in a variety of leadership roles in prescription drug development at Merck from 1985 to 1994. He was head of global clinical research operations, a group of approximately 225 that conducted clinical studies in all therapeutic areas worldwide. In 1994, he led the first external course for the Chinese FDA that covered GCP, clinical study design and data interpretation. Previous to that assignment, Dr. Berlin was head of international regulatory liaison, responsible for registration strategy development and execution in a wide variety of therapeutic areas.

Located in Fairfield, NJ, Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.

John H. Johnson
CEO, ImClone Systems, Inc.

John H. Johnson has more than two decades of executive and operational management experience in the biopharmaceutical and healthcare industries. Mr. Johnson has served as Chief Executive Officer of ImClone Systems since August 2007. He also served as a member of the companys Board of Directors. With offices in Branchburg, NJ, ImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. On November 24, 2008, ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY).

Prior to joining ImClone, Mr. Johnson served as Company Group Chairman of Johnson & Johnsons Worldwide Biopharmaceuticals unit and was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses, including Centocor, Inc., Ortho Biotech Products, L.P. and the Worldwide Strategic Marketing group.

Mr. Johnson began his healthcare career with Pfizer in 1983 where he held positions of increasing responsibility in Sales and Sales Management. He joined Johnson & Johnson in 1988 to help lead their entry into the anti-infectives business.

Christopher J. Schaber, Ph.D.
President and CEO, DOR BioPharma, Inc.

Christopher J. Schaber, Ph.D., has been DORs President and CEO and a director since August 2006. DOR BioPharma, Inc. (DOR) of Ewing, NJ is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents.

Prior to joining DOR, Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations.

During his tenure at Discovery Laboratories, Inc., Dr. Schaber played a significant role in raising in excess of $150 million through both public offerings and private placements. From 1996 to 1998, Dr. Schaber was a co-founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance and Drug Development. From 1994 to 1996, Dr. Schaber was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories.

About BioNJ
With 200 member companies, BioNJ is singularly focused on the growth and prosperity of New Jersey’ bioscience cluster.

Founded in 1994 by New Jersey bioscience industry CEOs, BioNJ serves as the voice of bioscience companies located in New Jersey, seeks to advance their economic growth and development and works to encourage new and established companies from around the world to locate here. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors.

# # #

CONTACT: Bill O’Donnell
Director of Public Affairs
O) 609-890-3185
C) 609-802-3091